logo
Millions of honeybees abuzz after truck overturns in Washington state

Millions of honeybees abuzz after truck overturns in Washington state

Yahoo01-06-2025
BELLINGHAM, Wash. (AP) — There was a buzz in the air Friday in northwestern Washington state as about 250 million honeybees escaped a commercial truck that overturned.
The truck hauling an estimated 70,000 pounds (31,751 kilograms) of honeybee hives rolled over around 4 a.m. close to the Canadian border near Lynden, the Whatcom County Sheriff's Office said in social media posts.
It appears the driver did not navigate a tight turn well enough, causing the trailer to roll into a ditch, county emergency management spokesperson Amy Cloud said in an email. The driver was uninjured, Cloud said.
Deputies, county public works employees and several bee experts responded to the scene. The box hives later came off the truck, and local beekeepers swarmed to help recover, restore and reset the hives, according to the sheriff's office.
The plan is to allow the bees to return to their hives and find their queen bee in the next day or two, according to the sheriff's office. The goal is to save as many of the bees as possible.
'Thank you to the wonderful community of beekeepers: over two dozen showed up to help ensure the rescue of millions of pollinating honey bees would be as successful as possible,' the sheriff's office post said.
The public was advised to avoid the area on Friday, and sheriff's deputies dove into in their squad cars at times to avoid being stung.
Honeybees are crucial to the food supply, pollinating over 100 crops including nuts, vegetables, berries, citrus and melons. Bees and other pollinators have been declining for years, and experts blame insecticides, parasites, disease, climate change and lack of a diverse food supply.
In 2018, the U.N. General Assembly sponsored the first 'World Bee Day' on May 20 to bring attention to the bees' plight.
Beekeepers often transport millions of bees from one location to another because leaving them in one location for too long can deplete resources for other pollinators, The Seattle Times reported.
Alan Woods, president of the Washington State Beekeepers Association, told the newspaper the state should have a standardized 'emergency bee response' for bee vehicle crashes. In 2015, 14 million bees escaped a truck north of Seattle on Interstate 5 and started stinging people, the newspaper reported at the time.
Lisa Baumann, The Associated Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Yahoo

time16 minutes ago

  • Yahoo

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising future in the market. 10 stocks we like better than Eli Lilly › Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for explosive growth. And today, the perfect example is weight loss drugs. Today's $28 billion weight loss drug market is on track to reach nearly $100 billion by 2030, according to Goldman Sachs Research, offering companies in the space an extremely solid opportunity over the next several years and likely beyond. Two names that have been making headlines in this field are Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX). The former is a current leader, already selling two blockbuster drugs prescribed for weight loss, and the latter is an up-and-coming player, with a candidate in late-stage trials. Which is the better growth buy today? Let's find out. Eli Lilly shares weight loss drug market leadership with fellow big pharma player Novo Nordisk. They each commercialize two drugs prescribed to people aiming to lose weight and have brought in billions of dollars in annual revenue. Here, I'll focus on Lilly. The company's drugs, Mounjaro and Zepbound, are actually the same compound, tirzepatide. But it's sold under the name Mounjaro for type 2 diabetes and under the name Zepbound for weight loss. The drug acts by stimulating hormonal pathways involved in the control of blood sugar levels and appetite. Thanks to the efficacy of tirzepatide, demand has soared, even surpassing supply until Lilly expanded its production capacity. But Lilly isn't sitting still in the area of weight loss. The company also is developing other drug candidates that may improve upon tirzepatide. The closest to market right now is orforglipron, Lilly's oral candidate for weight loss that recently delivered positive phase 3 trial results. If approved, it would be the only oral weight loss drug of its class that doesn't require strict food and water restrictions. Lilly aims on applying for regulatory review by the end of this year. All of this could result in more growth for Lilly this year and well into the future. Viking Therapeutics is a biotech company specializing in metabolic conditions, and it's made great progress with its obesity drug candidate, VK2735. The potential drug, in subcutaneous form, recently entered a phase 3 trial, and an oral form is involved in a phase 2 trial. These candidates are in the same class as tirzepatide, so work in the same way. Investors have shown their excitement about Viking's program in the past: When the company reported positive phase 2 data for the subcutaneous VK2735 last year, the stock soared more than 120% in one trading session. The stock hasn't maintained those gains, but the movement shows that investors are interested in the program -- and more good news ahead could boost the stock again. Now you might wonder why investors are so excited about Viking if there already are other successful weight loss drugs on the market -- and Lilly even is likely to reach commercialization with an oral weight loss drug ahead of Viking. This is because demand is high, and this is set to continue, so there is plenty of room for more than a couple of companies to succeed in the space. Investors also have speculated about the idea of a big pharma company acquiring Viking to get in on this high growth market. Lilly has the first-to-market advantage, is closer to the finish line with an oral candidate, and already is generating major revenue from its weight loss portfolio. Viking, if successful through clinical trials, could carve out market share and deliver major revenue growth down the road -- or the company could be acquired, offering investors another way to potentially gain. Each company offers certain advantages. Now let's answer our question. If all goes well for Viking, it could represent the better growth buy as, starting from zero product revenue today, this player could see revenue soar if and when it brings a weight loss drug to market. And we've seen that Viking's stock price is very reactive to news, meaning the stock could skyrocket in such a scenario. But, if you go the Viking route, you should be comfortable with risk as uncertainty remains: The company hasn't yet reached the finish line with a product. If you're more of a cautious investor, though, don't worry. You may opt for Lilly as, even though it's climbed 140% over the past three years, it still could have plenty of room to run over the long term thanks to this weight loss drug growth story. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Better Growth Buy: Eli Lilly vs. Viking Therapeutics was originally published by The Motley Fool

3 Cash-Heavy Stocks Worth Investigating
3 Cash-Heavy Stocks Worth Investigating

Yahoo

time16 minutes ago

  • Yahoo

3 Cash-Heavy Stocks Worth Investigating

A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital. Not all companies with sound capital structures are created equal, and StockStory is here to help you find the best. Keeping that in mind, here are three companies with net cash positions that can continue growing sustainably. Net Cash Position: $76.13 million (4.4% of Market Cap) Founded in 1987, American Superconductor (NASDAQ:AMSC) has shifted from superconductor research to developing power systems, adapting to changing energy grid needs and naval technology requirements. Why Are We Bullish on AMSC? Impressive 45% annual revenue growth over the last two years indicates it's winning market share this cycle Free cash flow margin is now positive, showing the company is at an important crossroads Improving returns on capital suggest its past investments are beginning to deliver value American Superconductor's stock price of $39.39 implies a valuation ratio of 75.2x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Net Cash Position: $259.3 million (2.4% of Market Cap) Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products. Why Is HIMS a Good Business? Average customer growth of 48.6% over the past two years demonstrates success in acquiring new clients that could increase their spending in the future Earnings per share have massively outperformed its peers over the last four years, increasing by 37% annually Free cash flow margin grew by 23.5 percentage points over the last five years, giving the company more chips to play with At $47.98 per share, Hims & Hers Health trades at 36.3x forward EV-to-EBITDA. Is now the right time to buy? See for yourself in our full research report, it's free. Net Cash Position: $299.7 million (9.4% of Market Cap) Founded in 2013 as a champion for content creator rights and free expression, Rumble (NASDAQ:RUM) is a video sharing platform that positions itself as a free speech alternative to mainstream platforms, offering creators more favorable revenue-sharing opportunities. Why Could RUM Be a Winner? Impressive 38.4% annual revenue growth over the last two years indicates it's winning market share this cycle Rumble is trading at $9.35 per share, or 21.9x trailing 12-month price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

In The AI Revolution, Medical Schools Are Falling Behind U.S. Colleges
In The AI Revolution, Medical Schools Are Falling Behind U.S. Colleges

Forbes

timean hour ago

  • Forbes

In The AI Revolution, Medical Schools Are Falling Behind U.S. Colleges

Instead of learning to use the tools that will define tomorrow's care, med school students still ... More memorize biochemistry pathways and obscure facts they'll never use in clinical practice. getty At Duke University, every matriculating student now has access to a custom AI assistant. At Cal State, more than 460,000 students across 23 campuses are equipped with a 24/7 ChatGPT toolkit upon enrollment. These aren't pilot programs. They're part of a full-scale transformation in the way higher education is preparing students for their future careers. Meanwhile, most U.S. medical schools remain stuck in the last century. Instead of learning to use the tools that will define tomorrow's care, students still memorize biochemistry pathways and are tested on obscure facts they'll never use in clinical practice. Following the release of OpenAI's ChatGPT in 2022, college deans and department chairs responded with caution. They worried about plagiarism, declining writing skills and an overreliance on artificial intelligence. Since, most have since shifted from risk avoidance to opportunity. Today, universities are integrating generative AI into tutoring, test prep, research, advising and more. Many now expect faculty to teach AI fluency across each of their disciplines. Medical education hasn't kept pace. A recent Educause study found that only 14% of medical schools have developed a formal GenAI curriculum compared with 60% of undergraduate programs. Most medical school leaders continue to view large language models as administrative tools rather than clinical ones. That's a mistake. By the time today's students become physicians, they'll carry in their pockets a tool more powerful and important to clinical practice than the stethoscope ever was. In seconds, GenAI can surface every relevant medical study, guideline and precedent. And soon, it will allow patients to accurately evaluate symptoms and understand treatment options before they ever set foot in a clinic. Used wisely, generative AI will help prevent the 400,000 deaths each year from diagnostic errors, the 250,000 from preventable medical mistakes and the 500,000 from poorly controlled chronic diseases. Despite GenAI's potential to transform healthcare, most medical schools still train students for the medicine of the past. They prioritize memorization over critical thinking and practical application. They reward students for recalling facts rather than for effectively accessing and applying knowledge with tools like ChatGPT or Claude. Historically, physicians were judged by how well they told patients what to do. In the future, success will be measured by medical outcomes. Specifically, how well clinicians and AI-empowered patients work together to prevent disease, manage symptoms and save lives. The outdated approach to medical education persists beyond university classrooms. Internship and residency programs still prioritize applicants for their memorization-based test scores. Attending physicians routinely quiz trainees on arcane facts instead of engaging in practical problem-solving. This practice, known as 'pimping,' is a relic of 20th-century training. Few industries outside of medicine would tolerate it. How To Modernize Medical Training Generative AI is advancing at breakneck speed, with capabilities doubling roughly every year. In five years, medical students will enter clinical practice with GenAI tools 32 times more powerful than today's models — yet few will have received formal training on how to use them effectively. Modernizing medical education must begin with faculty. Most students entering medical school in 2025 will already be comfortable using generative AI, having leaned on it during college and while preparing for the MCAT exam. But most professors will be playing catch-up. To close this gap, medical schools should implement a faculty education program before the new academic year. Instructors unfamiliar with GenAI would learn how to write effective prompts, evaluate the reliability of answers and ask clarifying questions to refine outputs. Once all faculty have a foundational understanding of the new applications, the real work begins. They need to create a curriculum for the coming semester. Here are two examples of what that might look like for third-year students on a clinical rotation: Exercise 1: Differential diagnosis with GenAI as a co-physician In a small-group session, students would receive a clinical vignette: A 43-year-old woman presents with fatigue, joint pain and a facial rash that worsens with sun exposure. Students would begin by first drafting their own differential diagnosis. Then, they would prompt a generative AI tool to generate its own list of potential diagnoses. Next, participants would engage the AI in a back-and-forth dialogue, questioning its reasoning, testing assumptions and challenging conclusions. To reinforce clinical reasoning in collaboration with GenAI, each student would also submit written responses to these questions: Is lupus or dermatomyositis the more likely diagnosis, and why? What additional data would help rule out Lyme disease? Cite three high-quality studies that support your diagnostic ranking. The goal of this type of exercise isn't to identify a 'right' answer but to strengthen analytical thinking, expose cognitive biases and teach students how to use GenAI to broaden diagnostic reasoning (not limit it). By the end of the exercise, students should be more confident using AI tools to support — but not replace — their own clinical judgment. Exercise 2: Managing chronic disease with GenAI support In this scenario, students imagine seeing a 45-year-old man during a routine checkup. The patient has no prior medical problems but, on physical exam, his blood pressure measures 140/100. Students begin by walking through the clinical reasoning process: What questions would they ask during the patient history? Which physical findings would be most concerning? What laboratory tests would they order? What initial treatment and follow-up plan would they recommend? Then, students enter the same case into a generative AI tool and evaluate its recommendations. Where do the AI's suggestions align with their own? Where do they differ (and why)? Finally, students are tasked with designing a patient-centered care plan that incorporates medical therapy, lifestyle changes and as many GenAI-powered applications as possible. These might include analyzing data from at-home blood pressure monitors, customizing educational guidance or enabling patients to actively manage their chronic diseases between visits. Training Physicians To Lead, Not Follow Colleges understand that preparing students for tomorrow's careers means teaching them how to apply generative AI in their chosen fields. Medicine must do the same. Soon, physicians will carry in their pocket the entirety of medical knowledge, instantly accessible and continuously updated. They'll consult AI agents trained on the latest research and clinical guidelines. And their patients, empowered by GenAI, will arrive not with random Google results, but with a working understanding of their symptoms, potential diagnoses and evidence-based treatment options. If medical schools don't prepare students to lead clinical application of these tools, for-profit companies and private equity firms will focus solely on ways to lower costs, even when these approaches compromise medical care. As medical school deans prepare to welcome the class of 2029, they must ask themselves: Are we training students to practice yesterday's medicine or to lead tomorrow's?

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store